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Abstract
Background: To date, no biomarkers with reasonable sensitivity and specificity for the early detection of malignant
mesothelioma have been described. The use of microRNAs (miRNAs) as minimally-invasive biomarkers has opened new
opportunities for the diagnosis of cancer, primarily because they exhibit tumor-specific expression profiles and have been
commonly observed in blood of both cancer patients and healthy controls. The aim of this pilot study was to identify
miRNAs in the cellular fraction of human peripheral blood as potential novel biomarkers for the detection of malignant
mesothelioma.
Methodology/Principal Findings: Using oligonucleotide microarrays for biomarker identification the miRNA levels in the
cellular fraction of human peripheral blood of mesothelioma patients and asbestos-exposed controls were analyzed. Using a
threefold expression change in combination with a significance level of p,0.05, miR-103 was identified as a potential
biomarker for malignant mesothelioma. Quantitative real-time PCR (qRT-PCR) was used for validation of miR-103 in 23
malignant mesothelioma patients, 17 asbestos-exposed controls, and 25 controls from the general population. For
discrimination of mesothelioma patients from asbestos-exposed controls a sensitivity of 83% and a specificity of 71% were
calculated, and for discrimination of mesothelioma patients from the general population a sensitivity of 78% and a
specificity of 76%.
Conclusions/Significance: The results of this pilot study show that miR-103 is characterized by a promising sensitivity and
specificity and might be a potential minimally-invasive biomarker for the diagnosis of mesothelioma. In addition, our results
support the concept of using the cellular fraction of human blood for biomarker discovery. However, for early detection of
malignant mesothelioma the feasibility of miR-103 alone or in combination with other biomarkers needs to be analyzed in a
prospective study.
Citation: Weber DG, Johnen G, Bryk O, Jo ¨ckel K-H, Bru ¨ning T (2012) Identification of miRNA-103 in the Cellular Fraction of Human Peripheral Blood as a Potential
Biomarker for Malignant Mesothelioma – A Pilot Study. PLoS ONE 7(1): e30221. doi:10.1371/journal.pone.0030221
Editor: Sumitra Deb, Virginia Commonwealth University, United States of America
Received August 3, 2011; Accepted December 14, 2011; Published January 11, 2012
Copyright:  2012 Weber et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The authors have no support or funding to report.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: weber@ipa-dguv.de
Introduction
Malignant mesothelioma (MM) is an incurable cancer of the
serous membranes and is highly associated with asbestos exposure.
In the United States, 18,068 MM cases were reported between
1999 and 2005 [1], with a projection of approximately
71,000 MM cases by 2054 [2]. Similar trends were also predicted
for Western Europe, with 250,000 deaths in the next 30–35 years
[3], and in many other countries worldwide [4]. The latency
period from asbestos exposure to tumor development is up to 40
years and symptoms usually appear in late stages of the disease.
Early diagnosis of tumors generally leads to more effective
therapies. Therefore, the same might be true for MM [5].
Biomarkers have the potential to facilitate an early diagnosis of
cancer. However, proper biomarkers need to be sensitive enough
to detect early stages of the tumors and highly specific to avoid
false-positive results in cancer-free individuals. Unfortunately,
none of the currently examined biomarkers, such as SMRP
(soluble mesothelin-related peptides), CA 125, and CYFRA 21-1,
either alone or in combination, serve as predictors for the early
diagnosis of MM [6,7].
The discovery of microRNAs (miRNAs) provided new oppor-
tunities for the use of biomarkers in the diagnosis of cancer [8].
MiRNAs are small (,22 nt) noncoding RNA molecules playing a
central role in the regulation of gene expression [9]. In cancer,
miRNAs act as either oncogenes or tumor suppressors [10].
Altered miRNA expression has been reported in several human
malignancies and differences in expression between tumor tissues
and their benign counterparts could be useful for cancer
diagnostics [11,12]. Several analyses of miRNA expression in
MM have already been performed resulting in the identification of
miRNAs as potential biomarkers [13–18]. However, most of the
studies analyzed miRNAs in tissues, while proper biomarkers
should be detectable in easily accessible samples. Alternatively,
miRNAs have also been found in body fluids [19–22]. Human
blood in particular is the preferred source of biomarkers due to the
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ization of most tissues, including tumors [23]. In human peripheral
blood, miRNAs were not only detectable in serum or plasma, but
also in the cellular fraction [24]. Recently, Ha ¨usler et al. showed
that neoplastic diseases generate characteristic miRNA finger-
prints in the cellular fraction of human peripheral blood [25].
In this pilot study, we analyzed miRNA expression in the
cellular fraction of peripheral human blood of malignant
mesothelioma patients (MMP) and asbestos-exposed controls
(AEC) using oligonucleotide microarrays. Significantly altered
miRNAs were selected as potential blood-based biomarkers for
MM and evaluated by quantitative real time-PCR (qRT-PCR) in
MMP, AEC, and additionally controls from the general
population (CGP).
Methods
Ethics statement
All participants provided written informed consent. The study
was designed according to rules guarding patient privacy and with
the approval from the ethics committee of the Ruhr-Universita ¨t
Bochum (reference number 3217-08).
Study population
The study group consisted of 23 patients with diagnosed pleural
MM (mean age 66 years, range 34–84 years). Patients were not
treated by surgery, chemotherapy, or radiation therapy before
Table 1. Characteristics of malignant mesothelioma patients
(MMP).
Sample Age Sex Smoking status Histological subtype*
MMP000 56 Female Ex Epithelioid
MMP001 84 Male Ex Biphasic
MMP002 54 Male Ex Biphasic
MMP003 68 Male No n.a.
MMP004 66 Female No Biphasic
MMP005 83 Female No Biphasic
MMP011 72 Male Ex Biphasic
MMP012 73 Male Ex n.a.
MMP013 70 Male No n.a.
MMP014 68 Male No Epithelioid
MMP026 76 Female Ex Epithelioid
MMP027 34 Male Ex Epithelioid
MMP028 70 Male No Biphasic
MMP029 59 Male No Epithelioid
MMP039 69 Female No Epithelioid
MMP040 74 Male No Epithelioid
MMP041 73 Male No Epithelioid
MMP042 72 Male No Sarcomatoid
MMP044 66 Male Ex Epithelioid
MMP045 73 Male Ex Biphasic
MMP056 53 Male No Epithelioid
MMP057 56 Male Ex Epithelioid
MMP060 51 Male n.a. Epithelioid
*All tumors are of pleural origin, n.a.: not available.
doi:10.1371/journal.pone.0030221.t001
Table 2. Characteristics of asbestos-exposed controls (AEC).
Sample Age Sex Smoking status
AEC001 61 Male Yes
AEC002 69 Male Yes
AEC004 67 Male Ex
AEC005 68 Male No
AEC008 77 Male Yes
AEC010 76 Male No
AEC011 60 Male Ex
AEC012 76 Male No
AEC014 79 Male No
AEC015 69 Male Ex
AEC016 67 Male Yes
AEC017 56 Male Ex
AEC018 80 Male No
AEC019 67 Male Yes
AEC020 47 Female No
AEC021 74 Male Ex
AEC022 62 Male Yes
doi:10.1371/journal.pone.0030221.t002
Table 3. Characteristics of controls from the general
population (CGP).
Sample Age Sex Smoking status
CGP001 63 Female No
CGP002 60 Male Yes
CGP003 57 Male Ex
CGP004 70 Male Ex
CGP005 64 Female Yes
CGP006 59 Female Yes
CGP007 77 Male No
CGP008 72 Male Ex
CGP009 64 Male Ex
CGP010 72 Male Yes
CGP011 71 Female No
CGP012 58 Male Yes
CGP013 76 Male Ex
CGP014 75 Male Ex
CGP015 66 Female Ex
CGP016 84 Male No
CGP017 77 Male Ex
CGP018 56 Male Ex
CGP019 62 Male Ex
CGP020 77 Male Ex
CGP021 81 Male Ex
CGP022 77 Male No
CGP023 71 Male Ex
CGP024 83 Female Ex
CGP025 66 Female Ex
doi:10.1371/journal.pone.0030221.t003
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toid, seven biphasic, and twelve epithelioid mesotheliomas. In
three cases, the histological subtype was unknown. Detailed
characteristics of patients with diagnosed mesothelioma are listed
in Table 1. The cancer-free control groups consisted of 17 subjects
formerly exposed to asbestos (mean age 68 years, range 47–80
years) and 25 volunteers from the general population (mean age 70
years, range 56–84 years). The volunteers were matched to the
mesothelioma group by age, gender, and smoking status (smoker,
ex-smoker, non-smoker). Detailed characteristics of the controls
are summarized in Table 2 and 3.
According to Wang et al., the case and control samples were not
split into training and test sets [8].
RNA isolation
From each participant, peripheral blood was collected in 9.0 ml
S-Monovette EDTA gel tubes (Sarstedt, Nu ¨mbrecht, Germany).
Within 30 minutes after blood collection, tubes were centrifuged
at 20006g for 10 minutes at room temperature. The cellular
fraction was separated from plasma and immediately stored at
220uC until RNA isolation. Samples were thawed at room
temperature and RNA isolation from 0.5 ml of the cellular
fraction was performed using the RiboPure-Blood Kit according
to the Alternate protocol: Isolation of Small RNAs (Applied
Biosystems, Foster City, CA, USA).
Concentration of isolated RNA was quantified by measuring the
absorbance at 260 nm using a NanoDrop ND-100 spectropho-
tometer (Thermo Scientific, Waltham, MA, USA).
Oligonucleotide microarrays
Oligonucleotide microarrays were purchased from the Norwe-
gian Microarray Consortium (www.microarray.no). The micro-
arrays were spotted using the mirVana miRNA Probe Set v2.0
(Ambion, Austin, TX, USA), which is based on the miRBase
Figure 1. Deregulated miRNAs in the cellular fraction of human blood of mesothelioma patients and asbestos-exposed controls.
Differences in miRNA expression were at least threefold. In patients with diagnosed malignant mesothelioma 15 miRNAs were up-regulated (green)
and 34 miRNAs were down-regulated (red).
doi:10.1371/journal.pone.0030221.g001
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using Pronto! Microarray spotting solution (Corning, Corning, NY,
USA) on CMT UltraGAPS (Corning) microarray slides. Hybrid-
ization of the microarrays was performed using the microarray
hybridization station HS 400 Pro (Tecan, Ma ¨nnedorf, Switzerland)
according to Liu et al. [27]. Microarray scanning at 635 nm and
signal definition were performed as described previously [28].
Labeling of 1 mg RNA was performed using 59-phosphate-
cytidyl-cytidyl-Cy5-39 (Eurogentec, Cologne, Germany) according
to the miRNA Microarray System Protocol (Agilent Technologies,
Santa Clara, CA, USA). Labeled RNA was purified using a mini
Quick Spin Column (Roche, Grenzach-Wyhlen, Germany)
centrifuging at 10006g for 10 minutes at room temperature.
Microarray platform and experimental data were deposited in
the public database Gene Expression Omnibus (GEO) (https://
www.ncbi.nlm.nih.gov/geo/). The series accession number is
GSE29707.
Microarray data analysis
Generated data were analyzed using the software GeneSpring
GX 11.0 (Agilent Technologies). In brief, data transformation
measurements less than 0.01 were set to 0.01 and normalization
per microarray was performed using the 50th percentile. For
analysis of altered miRNA expression between MMP and AEC a
fold change of 3.0 was used as threshold. Altered miRNAs with
fold-changes $3.0 were used for hierarchical clustering using
Euclidian distance and Ward’s linkage as parameters. Statistical
differences were analyzed utilizing the Mann-Whitney unpaired
test. For p-value correction the Westfall-Young-Permutation
method was used.
The stability of all human miRNAs throughout all samples was
analyzed using NormFinder [29]. According to Peltier and
Latham modified Z-scores were used as input data for NormFin-
der analysis [30].
Figure 2. Heat map of miRNA expression of malignant mesothelioma patients and asbestos-exposed controls. Cluster analysis was
performed using miRNA expressions with more than a threefold change in the cellular fraction of human peripheral blood samples. Samples of
malignant mesothelioma patients were marked blue and samples of asbestos-exposed controls yellow.
doi:10.1371/journal.pone.0030221.g002
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TaqMan miRNA Assays (Applied Biosystems) were used for
quantitative miRNA expression analysis on a 7900 HT Fast Real-
Time PCR System (Applied Biosystems) as described previously
[23,31]. 10 ng RNA and 5 ml cDNA were used as templates for
the RT reaction and PCR reaction, respectively. Samples were
analyzed in duplicate and non-template controls were included in
all assays.
A fixed threshold of 0.2 was used for cycle threshold (Ct)
estimation [32]. Ct values $35 were considered to be under the
detection limit [33] and marked as 35 for calculation [34]. Ratios
were calculated for normalization [23] and the expression value
was expressed as 2
2Ratio equivalent to 2
2dCt [35]. Mann-Whitney
unpaired tests were performed to examine differences in relative
miRNA expression of MMP vs. AEC, MMP vs. CGP, and AEC
vs. CGP as well as for subgroup comparisons regarding gender,
smoking status, and histological subtypes. The association of age
and miRNA levels was assessed using the Spearman correlation
coefficient. Statistical analyses were performed using Prism 5
(GraphPad Software Inc., San Diego, CA, USA).
Results
Deregulated miRNAs in the cellular fraction of peripheral
blood of MM patients
The expression profiles of 328 human miRNAs were deter-
mined in 23 MMP and 17 AEC using oligonucleotide microarrays.
In MMP, 49 miRNAs were deregulated with more than a
threefold change in comparison to AEC. In particular, 34
miRNAs were down-regulated and 15 miRNAs were up-
regulated. The deregulated miRNAs and the corresponding fold
changes are presented in Figure 1. The 49 miRNAs with more
than threefold change were used for hierarchical cluster analysis
utilizing Euclidian distance and Ward’s linkage (Figure 2).
Utilizing the Mann-Whitney unpaired test for statistical
significance and the Westfall-Young-Permutation method for p-
value correction, all deregulated miRNAs with more than a
threefold change were analyzed. Only two of 49 miRNAs, miR-
20a (p=0.0101) and miR-103 (p=0.0303), showed a significant
down-regulation in MM.
miR-20a and miR-103 as potential biomarkers for MM
The expression profiles of 328 human miRNAs in 23 MMP and
17 AEC samples were analyzed to reveal the most stable miRNA
as reference. Using NormFinder, miR-125a was identified as the
most stable miRNA in the analyzed set of MMP and AEC
samples. Thus, miR-125a was used as the reference to normalize
the raw Ct values of miR-20a and miR-103 obtained in the qRT-
PCR analysis.
Using normalized Ct values of miR-20a the median value and
interquartile range (IQR) were 0.668 (IQR 0.659–0.676) for MMP
and 0.682 (IQR 0.657–0.695) for AEC, but the observed
difference was not significant (data not shown). Median value of
miR-103 for MMP was 0.612 (IQR 0.608–0.620) and for AEC
Figure 3. Box plots of relative expression of miR-103. Relative expression of miR-103 in the cellular fraction of human peripheral blood of
malignant mesothelioma patients (blue), asbestos-exposed controls (yellow), and controls from the general population (orange). Expression values
were normalized to miR-125a and expressed as 2
2Ratio. Mann-Whitney test was performed to examine group differences.
doi:10.1371/journal.pone.0030221.g003
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(p=0.0062). For CGP median value of miR-103 was 0.630
(IQR 0.622–0.635) and differences were significant for MMP vs.
CGP (p,0.0001) but not for AEC vs. CGP (Figure 3).
Using normalized Ct values of miR-103, differences between
histological subtypes were analyzed. Median value of miR-103 was
0.611 (IQR 0.602–0.620) for epithelioid mesothelioma and 0.612
(IQR 0.610–0.614) for biphasic mesothelioma (Figure 4). No
significant differences between both subtypes could be observed.
The sarcomatoid subtype comprises only one sample and was not
included in the analysis.
Using ROC analysis for miR-103, an AUC value of 0.757 (95%
CI 0.586–0.929, p=0.0060) could be calculated for MMP vs.
AEC (Figure 5 A) and an AUC of 0.871 (95%CI 0.766–0.977,
p,0.0001) for MMP vs. CGP (Figure 5 B). A proper cut-off for
miR-103 using a 2
2Ratio value of 0.621 was determined to
discriminate MMP from AEC revealing a sensitivity of 83% and
specificity of 71%. Using the cut-off to discriminate MMP from
CGP reveals a sensitivity of 78% and a specificity of 76%.
Subgroup comparisons regarding gender, smoking status, and
age were performed using normalized Ct values of miR-103. For
male subjects the median value of miR-103 was 0.625 (IQR
0.612–0.636) and for female subjects 0.620 (IQR 0.614–0.629)
(Figure 6 A). Regarding the smoking status the median value of
miR-103 was 0.629 (IQR 0.622–0.642) for smokers, 0.624 (IQR
0.612–0.635) for ex-smokers, and 0.621 (IQR 0.612–0.634) for
non-smokers, (Figure 6 B). Using the Mann-Whitney test, no
significant differences could be observed for gender and smoking
status. The Spearman correlation coefficient was used to reveal
potential correlation between age and miRNA levels, revealing a
marginal association between age and miRNA level (rs=0.20,
95% CI 20.05–0.43), (Figure 6 C).
Discussion
Mesothelioma is a fatal cancer and chiefly associated with
former asbestos exposure. The tumor is commonly detected in late
stages of the disease. Blood-based biomarkers would greatly
improve diagnosis and early detection of MM [36]. It has been
suggested that miRNAs are promising biomarkers for several
human malignancies [24,37] and the same might be true for MM.
Most studies that analyzed miRNA expression in MM used tissues.
However, appropriate biomarkers need to be detectable in easily
accessible body fluids like peripheral blood. To date, miRNAs as
blood-based biomarkers for diagnosis of MM have not been
Figure 4. Scatter plot of relative expression of miR-103 in
histological subtypes of malignant mesothelioma. Relative
expression of miR-103 in the cellular fraction of human peripheral
blood of patients with epithelioid and biphasic mesothelioma. One
sarcomatoid mesothelioma case and three cases without available
histological subtype were excluded from analysis. Expression values
were normalized to miR-125a and expressed as 2
2Ratio.
doi:10.1371/journal.pone.0030221.g004
Figure 5. Receiver operating characteristics (ROC) curves of
miR-103. The area under curve (AUC) was determined for miR-103 in
the cellular fraction of human peripheral blood of (A) malignant
mesothelioma patients and asbestos-exposed controls and (B) malig-
nant mesothelioma patients and controls from the general population.
doi:10.1371/journal.pone.0030221.g005
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analyzed miR-126 as a free circulating nucleic acid in serum [15].
In this study, we analyzed the miRNA expression of MMP and
AEC in the cellular fraction of human peripheral blood to
identify specific miRNAs as potential biomarkers for MM. To
our knowledge, this is the first study analyzing miRNA in the
cellular fraction of human blood for biomarker evaluation of
MM. Our experimental design followed the recent study of
Ha ¨usler et al. who utilized this concept for miRNA expression
analysis in ovarian cancer [25]. They assumed that cancer-
induced miRNA profiles in cellular blood cells might already be
detectable at early stages in the development of tumors [25],
because it was shown that the formation of a pre-metastatic
niche by hematopoietic cells is an early event of tumorigenesis
and metastasis [38]. Ha ¨usler et al. assumed that free circulating
tumor-specific miRNAs in plasma or serum may be partly
masked by high amounts of cellular miRNAs, but this loss of
information is compensated for by the information revealed from
the cellular fraction [25]. For ovarian cancer they believe, that
stromal and myeloid progenitors or regulatory T cells, which are
recruited to the tumor site, may significantly contribute to the
miRNA profiles [25] and the same might be true for MM.
Further, tumors can send immuno-suppressive and pro-angio-
genic signals and induce the formation of pre-metastatic niches
by hematopoietic cells that may shape miRNA profiles in blood
cells. Because of these indirect effects of tumors on immune and
other circulating cells, the cellular fraction of human peripheral
blood might be an appropriate source for biomarker discovery,
even if miRNAs released from cancer cells become detectable in
plasma or serum when a significant tumor mass has been
accumulated [25].
The heat map of the 49 deregulated miRNAs showed an
imperfect clustering of the samples. While most of the cancer-free
samples clustered separately, some were dispersed within the
group of the malignant samples. The separation may be due to a
specific expression of miRNAs in benign diseases commonly
present in AEC as well as MMP, e.g., asbestosis or pleural plaques.
Thus, a detailed characterization of miRNA expression profiles in
benign (asbestos-associated) diseases is needed for better differen-
tiation between cases and controls. Furthermore, it is possible that
the miRNA expression pattern of AEC clustered between MMP
samples arises from early stages of MM when clinical symptoms
are still absent. In this case, the miRNA expression profile could
indicate an early diagnosis of cancer. However, a follow-up of the
AEC is needed to verify this assumption. In this study, the majority
of the deregulated miRNAs in MM are down-regulated. This is in
accordance with a global down-regulation of miRNAs commonly
described in cancer [39,40] and particularly in MM [15,17].
However, only miR-103 shows a significant down-regulation in
MM.
The identified miR-103 is part of the miR-15/107 group
commonly expressed in mammalian tissues [41]. The biological
Figure 6. Scatter plots of relative expression of miR-103.
Relative expression of miR-103 in the cellular fraction of human
peripheral blood of malignant mesothelioma patients (blue), asbestos-
exposed controls (yellow), and controls from the general population
(orange) regarding (A) gender, (B) smoking status, and (C) age. The
smoking status of one MMP case was not available. Expression values
were normalized to miR-125a and expressed as 2
2Ratio. Mann-Whitney
tests were performed to examine differences between groups.
Spearman correlation coefficient was calculated to evaluate association
between miR-103 levels and age.
doi:10.1371/journal.pone.0030221.g006
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metabolism, stress response, and angiogenesis, suggesting that the
deregulation of these miRNAs contribute to human diseases. In
fact, altered expression levels of the miR-15/107 group have been
observed in several human cancers [41]. For example, miR-103
and miR-107 are described as possible prognostic markers in
esophageal carcinoma [42]. To our knowledge, the present study
is the first to show a significant deregulation of miR-103 in MM,
including the two histological subtypes epithelioid and biphasic
mesothelioma.
Although previous works have shown miR-103 to be down-
regulated in several cancers [43], no previous investigation
analyzing miRNA expression in MM reported a deregulation of
miR-103 miRNA expression [13–18]. Such differences in miRNA
expression are probably caused by different study designs, mostly
regarding the selection of sample types. In this study, the cellular
fraction of peripheral blood was used; whereas others examined
formalin-fixed paraffin-embedded (FFPE) tissues [16], fresh tissues
[14,15,17], or cell cultures [13,18]. The variation in results may be
influenced by the size of the study collectives, which ranged
between seven [16] and 100 MM cases [18]. Furthermore, the use
of different controls, asbestos-exposed individuals in this study and
lung cancer patients [17], healthy individuals [18], or commer-
cially available pericardial RNA [14] in others may also be a
contributing factor. Additionally, in most studies microarrays were
used, which are prone to inconsistent results, mainly due to the
different microarray platforms [44].
Subgroup comparisons were performed to evaluate the
influence of the potential confounders gender, smoking status,
and age. Recently, distinct gender-specific expression patterns for
several miRNAs in male and female subjects were published [45].
In our study no gender-specific expression of miR-103 could be
observed. This is in accordance with Duttagupta et al., showing
no altered miR-103 expression between males and females [45].
A significant lower expression of miR-103 and other miRNAs
was described in older individuals [46]. Our study indicated also
altered miR-103 levels, but the effect was marginal. Thus, the age
of patients should always be taken into account and control
groups should be age-matched. The smoking status shows impact
on several biological mediators of inflammation [47] and thus,
may also influence the miRNA profile. In our study miR-103 is
not influenced by the smoking status. This is in accordance with
Guled et al., showing several smoking-related miRNAs in a
mesothelioma patients, but not miR-103 [14]. However, the
assigned subgroups were small, e.g., only 11 subjects were
smokers. Thus, the validity of the subgroup analyses is limited
and the obtained results may give only hints. A more detailed
confounder analysis in larger collectives considering several
potential influencing factors as published recently for SMRP,
CA 125, and CYFRA 21-1 [5] is needed to evaluate the real
impact of potential confounders.
To discriminate MMP from AEC and CGP, respectively, a
proper cut-off for miR-103 was determined utilizing ROC
analysis. The selected cut-off of 0.621 resulted in 83% sensitivity
and 71% specificity for MMP vs. AEC, and in 78% sensitivity and
84% specificity for MMP vs. CGP. The results imply that miR-103
is a potential biomarker of MM. In comparison to miR-126 (73%
sensitivity and 74% specificity) [15], miR-103 shows a comparable
specificity but slightly higher sensitivity. However, miR-126 has
been evaluated in a larger study group (44 mesothelioma patients,
196 asbestos-exposed controls, and 50 healthy controls) [15].
Therefore, the feasibility of miR-103 for detecting MM should also
be validated in larger collectives in order to obtain more reliable
values for sensitivity and specificity.
As a marker panel is more significant than a single marker for
the diagnosis of MM [7,48], it may be useful to evaluate miR-103
in combination with other biomarkers like SMRP [49] or
calretinin [36] to improve sensitivity and specificity. This was
already performed for miR-126 and SMRP, suggesting a potential
diagnostic biomarker combination for patients with early stages of
MM [15]. Nevertheless, to validate the performance of biomarkers
for the early detection of cancer, the most suitable design is a
prospective study [36].
In conclusion, in this pilot study we show the feasibility of the
cellular fraction of peripheral human blood for biomarker
discovery, suggesting a promising alternative to plasma or serum.
We evaluated miR-103 as a new potential biomarker for the
diagnosis of mesothelioma, showing a promising sensitivity and
specificity. The suitability of miR-103 alone and in combination
with other biomarkers for early detection of mesothelioma needs
to be further validated in a prospective study.
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